Vor Biopharma, Inc. (VOR)
NASDAQ:VOR
Want to see VOR full AI Analyst Report?
Top Page
Vor Biopharma
(NASDAQ:VOR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$13.00
▼(-21.64% Downside)
Action:Reiterated
Date:06/09/26
The score is primarily held down by weak financial performance (pre-revenue, widening losses, and sustained cash burn with negative equity) and bearish technicals (trading below key moving averages with negative MACD). Offsetting factors include constructive corporate events (China approval and new financing), while valuation metrics provide limited support because earnings are negative and no dividend yield is available.
Positive Factors
Low absolute debt
Very low reported debt limits interest burden and reduces short-term solvency risk for a pre-revenue biotech. This durable structural strength gives management more runway flexibility to prioritize clinical programs without heavy fixed financing costs, improving strategic optionality.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicates ongoing runway reliance on external capital. Over months this structural cash burn increases financing frequency risk, pressures strategic choices, and can force dilutive raises that affect long-term shareholder value and program pacing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low absolute debt
Very low reported debt limits interest burden and reduces short-term solvency risk for a pre-revenue biotech. This durable structural strength gives management more runway flexibility to prioritize clinical programs without heavy fixed financing costs, improving strategic optionality.
Read all positive factors
Vor Biopharma (VOR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$704.42M
Dividend YieldN/A
Average Volume (3M)783.71K
Price to Earnings (P/E)―
Beta (1Y)4.68
Revenue GrowthN/A
EPS Growth-1004.74%
CountryUS
Employees159
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-575.83
Shares Outstanding54,185,880
10 Day Avg. Volume688,556
30 Day Avg. Volume783,706
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.30K
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$33.80Price Target Upside103.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.71
Revenue Forecast (FY)N/A
Vor Biopharma Business Overview & Revenue Model
Company Description
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently unde...
How the Company Makes Money
null...
Vor Biopharma Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -28.00K | 0.00 | 0.00 | -3.49M | -8.96M | 0.00 |
| EBITDA | -1.13B | -368.75M | -117.66M | -114.37M | -83.13M | -67.58M |
| Net Income | -883.08M | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M |
Balance Sheet | ||||||
| Total Assets | 506.75M | 464.13M | 142.89M | 209.83M | 299.37M | 242.59M |
| Cash, Cash Equivalents and Short-Term Investments | 491.52M | 455.21M | 91.93M | 137.18M | 230.25M | 207.47M |
| Total Debt | 2.94M | 3.00M | 31.83M | 35.66M | 38.91M | 18.01M |
| Total Liabilities | 657.17M | 628.44M | 46.23M | 59.10M | 48.76M | 26.33M |
| Stockholders Equity | -150.42M | -164.31M | 96.66M | 150.72M | 250.61M | 216.26M |
Cash Flow | ||||||
| Free Cash Flow | -150.65M | -143.65M | -99.89M | -101.36M | -93.61M | -73.04M |
| Operating Cash Flow | -149.89M | -142.71M | -99.66M | -100.29M | -85.14M | -69.14M |
| Investing Cash Flow | -311.81M | -48.80M | 96.86M | 71.01M | -94.09M | -91.65M |
| Financing Cash Flow | 579.28M | 503.81M | 53.39M | 2.94M | 117.14M | 232.91M |
Vor Biopharma Technical Analysis
Negative
16.59
Price Trends
15.15
Negative
14.70
Negative
18.70
Negative
Market Momentum
-0.51
Positive
40.05
Neutral
19.10
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Negative. The current price of 16.59 is above the 20-day moving average (MA) of 14.36, above the 50-day MA of 15.15, and below the 200-day MA of 18.70, indicating a bearish trend. The MACD of -0.51 indicates Positive momentum. The RSI at 40.05 is Neutral, neither overbought nor oversold. The STOCH value of 19.10 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VOR.
Vor Biopharma Risk Analysis
Vor Biopharma disclosed 82 risk factors in its most recent earnings report. Vor Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vor Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $213.61M | -6.67 | -68.09% | ― | 56.76% | 63.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $465.69M | -2.96 | -81.87% | ― | ― | 2.58% | |
49 Neutral | $106.01M | -2.45 | -36.37% | ― | -100.00% | -1056.82% | |
49 Neutral | $351.32M | -2.05 | -57.01% | ― | ― | -28.75% | |
46 Neutral | $704.42M | >-0.01 | 87.31% | ― | ― | -1004.74% | |
46 Neutral | $177.53M | -1.29 | -100.13% | ― | 12.96% | 12.51% |
* Healthcare Sector Average
VOR
Vor Biopharma
13.00
8.86
214.01%
CDXS
Codexis
2.35
0.10
4.44%
BDTX
Black Diamond Therapeutics
1.85
-0.58
-23.87%
AVIR
Atea Pharmaceuticals
4.39
1.18
36.76%
CRBU
Caribou Biosciences
1.79
0.63
54.31%
KYTX
Kyverna Therapeutics, Inc.
7.66
4.20
121.39%
Vor Biopharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
Vor Bio gains boost from telitacicept IgA nephropathy approval
Positive
Jun 8, 2026
Vor Bio and its collaborator RemeGen Co., Ltd. reported on June 8, 2026, that China’s National Medicinal Products Administration granted conditional approval for telitacicept to treat adult patients with IgA nephropathy in China. The decisio...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Vor Biopharma Announces $75 Million Private Placement Financing
Positive
Mar 27, 2026
On March 26, 2026, Vor Biopharma Inc. entered into a securities purchase agreement with healthcare investment firm TCGX for a $75 million private placement of 5,338,078 common shares at $14.05 per share, with closing expected around March 30, 2026...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.